Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 22, 2020New England Journal of MedicineOpen Access

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

RZRobert ZeiserUniversity of FreiburgNBNikolas von BubnoffUniversitäres Kinderwunschzentrum LübeckJBJason ButlerRoyal Brisbane and Women's Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zeiser et al. (2020) studied this question.

synapsesocial.com/papers/69d90dcbcc20f7a91c3afed1https://doi.org/10.1056/nejmoa1917635
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update2011 · 196 citations
  2. 2Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective2009 · 1,804 citations
  3. 3Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease2015 · 34 citations
  4. 4International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium2015 · 1,030 citations
  5. 5Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin2006 · 168 citations